Research programme: neurodegenerative disease therapies -Charles River Laboratories/Eisai

Drug Profile

Research programme: neurodegenerative disease therapies -Charles River Laboratories/Eisai

Latest Information Update: 10 Mar 2016

Price : $50

At a glance

  • Originator Eisai Co Ltd
  • Developer Charles River Laboratories; Eisai Co Ltd
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Neurodegenerative disorders

Most Recent Events

  • 15 Feb 2016 Early research in Neurodegenerative disorders in USA, United Kingdom and Japan (unspecified route)
  • 15 Feb 2016 Eisai Co Ltd and Charles River Laboratories collaborate to develop Neurodegenerative disease therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top